Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor (ASI) being studied for hypertension and related cardiometabolic conditions. The company has no approved products or commercial revenue yet and is building value through clinical development, regulatory progress, and intellectual property protection.

43.76

43.76

— Mineralys Therapeutics, Inc.
%
Lead product candidate100% Lorundrostat is the company's lead investigational therapy for hypertension and potential adjacent indications.
Clinical development services0% Internal and outsourced R&D activities supporting preclinical and clinical advancement of lorundrostat.
Regulatory and commercial preparation0% Activities to prepare for potential FDA approval, launch planning, and market access.

Mineralys does not yet sell approved products, so it does not have commercial customers today...

  • Hypertension patientsprimary

    Potential end users of lorundrostat if approved, especially patients needing additional blood pressure control.

  • Physicians and clinical prescribersprimary

    Doctors would decide whether to prescribe lorundrostat based on efficacy, safety, and convenience.

  • Healthcare payorsprimary

    Medicare, Medicaid, and private insurers would determine coverage and reimbursement access.

  • Clinical research and manufacturing partnerssecondary

    CROs, consultants, and contract manufacturers support development and supply before commercialization.

Mineralys is headquartered in the United States and its current operations are primarily U.S.-based...

  • •Headquartered in Radnor, Pennsylvania, United States
  • •Clinical development and corporate operations are primarily U.S.-based
  • •U.S. FDA approval is the key regulatory gate for commercialization
  • •U.S. payor and pricing policy will shape future market access
  • •No country-level revenue disclosed because the company has no product sales

The company’s strategy is to advance lorundrostat through clinical development, secure regulatory approval, and then...

01
Complete clinical development of lorundrostatshort-term

Approval depends on demonstrating efficacy and safety in hypertension studies.

02
Maintain financing runwayshort-term

The company has no product revenue and must fund R&D through external capital.

03
Prepare for commercializationmedium-term

Launch success will depend on manufacturing, access, and sales model decisions.

Mineralys is a pre-revenue biotech with a single lead asset, so its risk profile is dominated by clinical, regulatory,...

critical

Clinical development failure for lorundrostat

The company’s value is concentrated in one lead candidate, so trial setbacks would materially reduce prospects.

Scope
Hypertension and related indications
Materiality
high
high

Financing risk and dilution

The company has no product revenue and expects to fund operations through external capital.

Scope
Equity offerings, debt, collaborations
Materiality
high
high

Manufacturing and supply chain dependence

Mineralys relies on third-party contract manufacturers for APIs and finished product candidates.

Scope
Clinical supply and future commercial supply
Materiality
medium
high

Commercial reimbursement and pricing pressure

Even if approved, uptake depends on coverage and acceptable reimbursement from payors.

Scope
Medicare, Medicaid, private insurers
Materiality
high
high

Competitive intensity in hypertension

Existing standard-of-care generics and multiple novel programs could limit market share.

Scope
ARBs, ACE inhibitors, diuretics, MRAs, ASIs
Materiality
high
Prepaid and accrued research and development expenses
Affects operating loss and quarterly comparability
Clinical trial cost timing
Can cause large quarter-to-quarter swings in operating expenses
Stock-based compensation
Raises reported operating costs without immediate cash outflow
License agreement accounting
Could affect future expense recognition and disclosures

Inhibikase Therapeutics, Inc.

IKT · Biological Products, (No Diagnostic Substances)

Kairos Pharma, LTD.

KAPA · Pharmaceutical Preparations

CytoDyn Inc.

CYDY · Pharmaceutical Preparations

Mereo BioPharma Group plc

MREO · Pharmaceutical Preparations

Inhibitor Therapeutics, Inc.

INTI · Pharmaceutical Preparations

Edgewise Therapeutics, Inc.

EWTX · Pharmaceutical Preparations

: 28/04/2026